A tech investor’s rude awakening on clinical trials sparks an effort to make them faster for Covid-19
When Sam Altman, the CEO of artificial intelligence firm OpenAI and a well-known tech investor, saw the pandemic coming, he started investing in biotech companies that could combat it, and fast. Eventually, he had funded roughly 20 different efforts, a mix of investments and philanthropy.
“I think people always try to help in any situation the way they know how,” Altman said. “The one thing I know how to do is fund companies.”
